Literature DB >> 12066216

Fas expression inversely correlates with metastatic potential in osteosarcoma cells.

Laura L Worth1, Elizabeth A Lafleur, Shu-Fang Jia, Eugenie S Kleinerman.   

Abstract

A complex series of steps must take place to allow for a single cell to metastasize. Identifying factors responsible for these steps is essential in developing targeted therapy. We developed series of osteosarcoma cell lines with differing metastatic potentials. We used them to investigate mechanisms of metastasis and possible therapeutic targets for osteosarcoma metastasis to the lung in a nude mouse model. No correlation was found between epidermal growth factor receptor (EGFR), insulin-like growth factor receptor inhibitor (IGF-I-R), gelatinase, p53, metalloproteinase 9 (MMP 9), platelet derived growth factor receptor (PDGF-R), vascular endothelial growth factor (VEGF) and c-met expression and metastatic potential as measured by Northern analysis. By contrast, Fas expression inversely correlated with metastatic potential, and manipulation of Fas expression altered the metastatic phenotype of the cell. Our data indicate that fas gene expression may offer a new therapeutic target for the treatment of metastatic osteosarcoma in the lung.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12066216

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  30 in total

1.  Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine.

Authors:  Nancy Gordon; Nadezhda V Koshkina; Shu-Fang Jia; Chand Khanna; Arnulfo Mendoza; Laura L Worth; Eugenie S Kleinerman
Journal:  Clin Cancer Res       Date:  2007-08-01       Impact factor: 12.531

Review 2.  Aerosol therapy for the treatment of osteosarcoma lung metastases: targeting the Fas/FasL pathway and rationale for the use of gemcitabine.

Authors:  Nancy Gordon; Eugenie S Kleinerman
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2010-08       Impact factor: 2.849

3.  Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. a report from the Children's Oncology Group.

Authors:  Carola A S Arndt; Nadya V Koshkina; Carrie Y Inwards; Douglas S Hawkins; Mark D Krailo; Doojduen Villaluna; Peter M Anderson; Allen M Goorin; Martin L Blakely; Mark Bernstein; Sharon A Bell; Kaylee Ray; Darryl C Grendahl; Neyssa Marina; Eugenie S Kleinerman
Journal:  Clin Cancer Res       Date:  2010-06-24       Impact factor: 12.531

4.  Biomarkers in Osteosarcoma.

Authors:  Colin Kong; Marc F Hansen
Journal:  Expert Opin Med Diagn       Date:  2009-01-01

5.  miR-20a encoded by the miR-17-92 cluster increases the metastatic potential of osteosarcoma cells by regulating Fas expression.

Authors:  Gangxiong Huang; Kazumasa Nishimoto; Zhichao Zhou; Dennis Hughes; Eugenie S Kleinerman
Journal:  Cancer Res       Date:  2011-12-20       Impact factor: 12.701

6.  Expression of c-FLIP in pulmonary metastases in osteosarcoma patients and human xenografts.

Authors:  Krithi Rao-Bindal; Chethan K Rao; Ling Yu; Eugenie S Kleinerman
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

7.  Biological properties and gene expression associated with metastatic potential of human osteosarcoma.

Authors:  Tetsuhiro Nakano; Masachika Tani; Yasunori Ishibashi; Kenji Kimura; Yong-Bum Park; Natsuko Imaizumi; Hiroyuki Tsuda; Kazuhiko Aoyagi; Hiroki Sasaki; Susumu Ohwada; Jun Yokota
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

Review 8.  Nanocapsule Delivery of IL-12.

Authors:  Justin E Markel; Ryan A Lacinski; Brock A Lindsey
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

Review 9.  The Histone Deacetylase Inhibitor Entinostat/Syndax 275 in Osteosarcoma.

Authors:  Simin Kiany; Douglas Harrison; Nancy Gordon
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

10.  miR-20a Regulates FAS Expression in Osteosarcoma Cells by Modulating FAS Promoter Activity and Can be Therapeutically Targeted to Inhibit Lung Metastases.

Authors:  Yuanzheng Yang; Gangxiong Huang; Zhichao Zhou; Jason G Fewell; Eugenie S Kleinerman
Journal:  Mol Cancer Ther       Date:  2017-10-27       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.